5,355 results match your criteria Lymphoma Mantle Cell


Metachronous Sigmoid Carcinoma and Mantle Cell Lymphoma in Intestines.

Case Rep Gastroenterol 2019 Jan-Apr;13(1):17-24. Epub 2019 Jan 10.

Department of Pathology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.

It is rare that colon carcinoma and mantle cell lymphoma (MCL) occur one after another in intestines. We found two malignancies of sigmoid carcinoma and MCL in a single patient, who had initially been diagnosed with sigmoid carcinoma and treated with radical resection in our hospital. Good postoperative recovery was reported without recurrence signs, which lasted for 7 years and 5 months until polyps of sigmoid colon were found by colonoscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381904PMC
January 2019

A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy.

J Immunother Cancer 2019 Feb 21;7(1):51. Epub 2019 Feb 21.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Background: The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0529-9DOI Listing
February 2019

Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma.

Drug Saf Case Rep 2019 Feb 21;6(1). Epub 2019 Feb 21.

Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

A 70-year-old Japanese man with mantle cell lymphoma underwent extensive chemotherapy and radiation because of the relapse of mantle cell lymphoma. He developed mediastinal emphysema and a pneumothorax 14 days after treatment with 560 mg of ibrutinib. The mediastinal emphysema and the right pneumothorax disappeared after the ibrutinib treatment was tapered off. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40800-019-0098-3DOI Listing
February 2019

Expression of GNAZ, encoding the Gα protein, predicts survival in mantle cell lymphoma.

Br J Haematol 2019 Feb 20. Epub 2019 Feb 20.

Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Mantle cell lymphoma (MCL), a malignancy of B-lymphocytes, has a poor prognosis. It is thus necessary to improve the understanding of the pathobiology of MCL and identify factors contributing to its aggressiveness. Our studies, based on Affymetrix data from 17 MCL biopsies, real-time quantitative polymerase chain reaction data from 18 sorted primary MCL cells and 108 MCL biopsies compared to non-malignant tissue, reveals that GNAZ expression predicts poor clinical outcome of MCL patients (Cox regression, P = 0·014) and lymphocytosis (Mann-Whitney, P = 0·011). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15810DOI Listing
February 2019

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

PLoS One 2019 20;14(2):e0211228. Epub 2019 Feb 20.

Serviço de Cardiologia, Hospital Universitário de Santa Maria (CHLN), CAML, Centro Cardiovascular da Universidade de Lisboa-CCUL, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, Portugal.

Introduction: Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is unknown, and hypertension may play a role in the pathogenesis of this adverse drug reaction.

Methods: We aimed to review the risk of hypertension and atrial fibrillation as adverse events associated with ibrutinib through a systematic review with meta-analysis of randomized controlled trials (RCTs) retrieved in December 2018 on MEDLINE, EMBASE, CENTRAL and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211228PLOS
February 2019
3.234 Impact Factor

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019

Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas.

Methods Mol Biol 2019 ;1956:139-155

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Comprehensive analysis of the clonotypic B cell receptor immunoglobulin (BcR IG) gene rearrangement sequences in patients with mature B cell neoplasms has led to the identification of significant repertoire restrictions, culminating in the discovery of subsets of patients expressing highly similar, stereotyped BcR IG. This finding strongly supports selection by common epitopes or classes of structurally similar epitopes in the ontogeny of these tumors. BcR IG stereotypy was initially described in chronic lymphocytic leukemia (CLL), where the stereotyped fraction of the disease accounts for a remarkable one-third of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_7DOI Listing
January 2019

Apremilast in a patient with psoriasis and mantle cell lymphoma under maintenance treatment with rituximab.

Authors:
Wiebke K Peitsch

J Dtsch Dermatol Ges 2019 Feb 18. Epub 2019 Feb 18.

Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13771DOI Listing
February 2019
1 Read

Endoscopic image of gastrointestinal involvement by mantle cell lymphoma.

Gastroenterol Hepatol 2019 Feb 12. Epub 2019 Feb 12.

Servicio de Digestivo, Hospital Universitario Sanitas La Moraleja, Madrid, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gastrohep.2018.12.003DOI Listing
February 2019
1 Read

SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients.

Am J Surg Pathol 2019 Feb 12. Epub 2019 Feb 12.

Departments of Hematopathology.

Studies have suggested that SOX11 expression has prognostic implications in patients with mantle cell lymphoma (MCL), but the data are controversial. In this study, we describe the clinicopathologic and prognostic features of 75 patients with SOX11-negative MCL. Compared with patients with SOX11-positive MCL, SOX11-negative MCL patients more frequently had leukemic non-nodal disease (21% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001233DOI Listing
February 2019
1 Read

Chylous Ascites due to Mantle Cell Lymphoma.

Eur J Case Rep Intern Med 2018 26;5(6):000871. Epub 2018 Jun 26.

Internal Medicine Department, Centro Hospitalar de Vila Nova de Gaia-Espinho, Portugal.

Chylous ascites is rare and results in accumulation of lymph in the abdominal cavity, due to several mechanisms. The ascitic liquid is milky because of the high concentration of triglycerides (>200 mg/dl). The higher incidence compared to the past is explained by increased survival of patients with cancer and more aggressive surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2018_000871DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346885PMC
June 2018
1 Read

Ibrutinib plus Palbociclib Has Efficacy in Mantle Cell Lymphoma.

Authors:

Cancer Discov 2019 Feb 8. Epub 2019 Feb 8.

The BTK inhibitor ibrutinib plus the CDK4 inhibitor palbociclib achieves responses in 67% of MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-RW2019-016DOI Listing
February 2019
1 Read

Mantle cell lymphoma and its management: where are we now?

Exp Hematol Oncol 2019 30;8. Epub 2019 Jan 30.

1Upstate Cancer Center, State University Of New York Upstate Medical University, SUNY Upstate Cancer Center, Suite 331, CWB, 750 E. Adams Street, Syracuse, NY 13210 USA.

Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5-6% non-Hodgkin's lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this disease a research focus to both experimental oncology and clinical oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-019-0126-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354396PMC
January 2019
1 Read

A patient with a diagnosis of nodal marginal zone B-cell lymphoma and a t(2;14)(p24;q32) involving and .

Mol Cytogenet 2019 1;12. Epub 2019 Feb 1.

Department of Pathology, Nelson Hospital, 115 Kawai St, Nelson South, Nelson, 7010 New Zealand.

Background: Nodal marginal zone B-cell lymphoma is a rare entity in which the cytogenetic findings are not well defined. The t(2;14)(p24;q32) has previously been reported in three patients with blastic mantle cell lymphoma and one patient with follicular lymphoma. This rearrangement has not been reported previously in a patient with a diagnosis of nodal marginal zone B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13039-019-0419-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359751PMC
February 2019
1 Read

Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.

Sci Signal 2019 Feb 5;12(567). Epub 2019 Feb 5.

Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 0429, Houston, TX 77030-4009, USA.

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma that is largely chemoresistant. Ibrutinib, a drug that inhibits Bruton's tyrosine kinase (BTK), has improved the overall survival of patients with MCL; however, resistance to ibrutinib has emerged as a decisive, negative factor in the prognosis of MCL. Adopting a more patient-centric therapeutic approach that incorporates applied genomics and interrogation of B cell signaling pathways may offer an alternative route to reach durable remission in patients with MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aat4105DOI Listing
February 2019
2 Reads
6.279 Impact Factor

Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.

Oncotarget 2018 Dec 28;9(102):37753-37765. Epub 2018 Dec 28.

Department of Oncological Sciences, Icahn School of Medicine, New York 10029, NY, USA.

Overexpression and constitutive activation of CYCLIN D1 and Casein Kinase 2 are common features of many hematologic malignancies, including mantle cell lymphoma (MCL) and leukemias such as T-cell acute lymphoblastic leukemia (T-ALL). Although both CK2 and CDK4 inhibitors have shown promising results against these tumor types, none of these agents have achieved objective responses in the clinic as monotherapies. Because both proteins play key roles in these and other hematological malignancies, we have analyzed the therapeutic potential of ON108110, a novel dual specificity ATP-competitive inhibitor of protein kinase CK2 as well as CDK4/6 in MCL and T-ALL. Read More

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26514
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26514DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340882PMC
December 2018
5 Reads

Mantle cell lymphoma-rare differential diagnosis of a tumor in the vermiform appendix.

J Surg Case Rep 2019 Jan 24;2019(1):rjy367. Epub 2019 Jan 24.

Department of General Surgery, Cantonal Hospital of Lucerne, Spitalstrasse, 6000 Lucerne 16, Switzerland.

Although the most common localization of extranodal non-Hodgkin lymphoma is the gastrointestinal system, the infiltration of the vermiform appendix is a very rare condition. We report a case of mantle cell lymphoma affecting the appendix as an incidental finding due to gynecological surgery. A 57-year-old woman presented with increasing pain in the right lower abdomen since months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjy367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344925PMC
January 2019
1 Read

Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.

Leuk Lymphoma 2019 Jan 30:1-13. Epub 2019 Jan 30.

f GW Cancer Center, George Washington University , Washington , DC , USA.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation. This translocation most often results in overexpression of cyclin D1. MCL is clinically heterogeneous, outcomes are generally poor, and no standard treatment has been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571205DOI Listing
January 2019
1 Read

Contribution of Inhibition of Protein Catabolism in Myeloma.

Cancer J 2019 Jan/Feb;25(1):11-18

From the Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Multiple myeloma (MM) is a cancer of plasma cells, characterized by abundant synthesis of monoclonal immunoglobulins and/or free light chains. Although MM remains incurable, median overall survival has considerably improved over the past 2 decades largely due to the introduction of novel agents, including proteasome inhibitors (PIs) and immunomodulatory drugs. Bortezomib, a reversible boronate PI, was the first Food and Drug Administration-approved PI in MM and subsequently mantle cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000349DOI Listing
January 2019
5 Reads

A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Blood 2019 Jan 28. Epub 2019 Jan 28.

Meyer Cancer Center, Department of Medicine, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, United States.

Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment failure during the first year. We previously demonstrated that prolonged early G1 cell cycle arrest induced by the oral, specific CDK4/6 inhibitor palbociclib can overcome ibrutinib resistance in primary human MCL cells and MCL cell lines expressing wild-type BTK. Therefore, we conducted a phase I trial to evaluate the dosing, safety and preliminary activity of palbociclib plus ibrutinib in patients with previously treated mantle cell lymphoma (NCT02159755). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-886457DOI Listing
January 2019
1 Read

18F-FDG PET/CT in Intramuscular Mantle Cell Lymphoma With Elongated Lymphomatous Neurovascular Extension.

Clin Nucl Med 2019 Jan 25. Epub 2019 Jan 25.

From the Institute of Nuclear Medicine and Molecular Imaging, Soroka University Medical Center, Affiliated to Ben Gurion University of the Negev, Faculty of Health Sciences, Beer-Sheva, Israel.

Skeletal muscle involvement by lymphoma is rare, particularly for mantle cell lymphoma. We describe a 65-year-old man who presented with a rapidly growing left thigh mass. FDG PET/CT characterized the mass as malignant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002466DOI Listing
January 2019
1 Read

In brief: Acalabrutinib (Calquence) for mantle cell lymphoma.

Authors:

Med Lett Drugs Ther 2018 Nov 5;60(1559):e184. Epub 2018 Nov 5.

View Article

Download full-text PDF

Source
November 2018
1 Read

Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients.

Dig Dis 2019 Jan 24:1-7. Epub 2019 Jan 24.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Background: The frequency of endoscopically apparent gastrointestinal tract (GI) involvement in patients with mantle cell lymphoma (MCL) at diagnosis is thought to be in the range of 30%. While reports on GI involvement in MCL patients exist, most series lack a strict GI assessment due to the often asymptomatic nature of GI involvement. Owing to the standardized staging routine at our institution including GI assessment at diagnosis, we have analyzed the rate and prognostic impact of GI involvement in MCL. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496508
Publisher Site
http://dx.doi.org/10.1159/000496508DOI Listing
January 2019
3 Reads

Nasopharyngeal Mantle Cell Lymphoma: An Extremely Rare Entity.

Oman Med J 2019 Jan;34(1):74-77

Department of Otorhinolaryngology-Head and Neck Surgery, Universiti Sains Malaysia Health Campus, Kelantan, Malaysia.

Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin lymphoma with a poor prognosis and high recurrence rate. It seldom affects the Waldeyer's ring let alone the nasopharynx. Patients usually present at late stages of the disease leading to poor failure-free and overall survival rates. Read More

View Article

Download full-text PDF

Source
http://omjournal.org/articleDetails.aspx?coType=1&aId=24
Publisher Site
http://dx.doi.org/10.5001/omj.2019.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330188PMC
January 2019
6 Reads

Bronchial Involvement in Mantle Cell Lymphoma.

Arch Bronconeumol 2019 Jan 18. Epub 2019 Jan 18.

Servicio de Neumología y Alergia, Instituto Clínico Respiratorio, Hospital Clínic, Barcelona, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.arbres.2018.12.004DOI Listing
January 2019
1 Read

Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.

Leukemia 2019 Jan 21. Epub 2019 Jan 21.

Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kanas City, KS, USA.

p97 is an ATPase that works in concert with histone deacetylase 6 (HDAC6), to facilitate the degradation of misfolded proteins by autophagosomes. p97 has also been implicated in DNA repair and maintaining genomic stability. In this study, we determined the effect of combined inhibition of p97 and HDAC6 activities in mantle cell lymphoma (MCL) cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0355-yDOI Listing
January 2019
2 Reads
10.431 Impact Factor

The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.

Mol Oncol 2019 Jan 20. Epub 2019 Jan 20.

Translational Medicine Research Center, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B-cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti-cancer activity of ibrutinib against solid tumors, such as non-small cell lung cancer (NSCLC), remains low. To improve the cytotoxicity of ibrutinib towards lung cancer, we synthesized a series of ibrutinib derivatives, of which Ibr-7 exhibited superior anti-cancer activity to ibrutinib, especially against epithelial growth factor receptor (EGFR) wild-type NSCLC cell lines. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/1878-0261.12454
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12454DOI Listing
January 2019
5 Reads
5.331 Impact Factor

TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.

Cancer Immunol Res 2019 Jan 18. Epub 2019 Jan 18.

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize antitumor T-cell responses. Read More

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0351DOI Listing
January 2019
8 Reads

Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.

Am J Hematol 2019 Jan 16. Epub 2019 Jan 16.

Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin.

Chimeric antigen receptor modified T (CAR-T) cell therapy against the CD19 antigen has revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non-Hodgkin lymphoma (NHL). Currently, there are two FDA approved products (axicabtagene ciloleucel and tisagenlecleucel) for B cell NHL, with several other constructs under clinical investigation. This review will focus on the clinical outcomes, toxicity profile, and differences among candidate CD19 CAR-T cell products for major subtypes of B cell NHL including diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25403DOI Listing
January 2019
3 Reads

[Ocular adnexal mantle cell lymphoma: a clinicopathological analysis of nine cases].

Zhonghua Bing Li Xue Za Zhi 2019 Jan;48(1):37-39

Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.01.008DOI Listing
January 2019
1 Read

Sensitive quantification of the intronless SOX11 mRNA from lymph nodes biopsies in mantle cell lymphoma.

Leuk Res 2019 Mar 3;78:1-2. Epub 2019 Jan 3.

Haematology-Pathology Research Laboratory, Odense University Hospital, Denmark; Department of Haematology, Odense University Hospital, Denmark. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.001DOI Listing
March 2019
1 Read

Acalabrutinib for adults with mantle cell lymphoma.

Expert Rev Clin Pharmacol 2019 Mar 26;12(3):179-187. Epub 2019 Jan 26.

b Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1568868DOI Listing
March 2019
12 Reads

Primary Colorectal Follicular Lymphoma in 3 Dogs.

Vet Pathol 2019 Jan 13:300985818823775. Epub 2019 Jan 13.

1 Department of Pathobiology and Diagnostic Investigation, Veterinary Diagnostic Laboratory, Michigan State University, Lansing, MI, USA.

Primary colorectal follicular lymphomas are rare indolent lymphoid neoplasms in humans that have not been reported in dogs. We describe 3 cases of primary colorectal follicular lymphoma in dogs with histologic and immunohistochemical features similar to their human counterpart. Initial clinical signs in all dogs included tenesmus, hematochezia, and a palpable rectal mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985818823775DOI Listing
January 2019
2 Reads

Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma.

Vet Pathol 2019 Jan 13:300985818823668. Epub 2019 Jan 13.

1 Michigan State University Veterinary Diagnostic Laboratory and Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA.

Marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) belong to a subgroup of indolent B-cell lymphomas most commonly reported in the canine spleen. The goal of this study was to characterize the immunophenotype of splenic MZL and MCL in comparison to their human counterparts. Ten MCLs and 28 MZLs were selected based on morphology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300985818823668DOI Listing
January 2019
8 Reads

LINK-A lncRNA Promotes Proliferation and Inhibits Apoptosis of Mantle Cell Lymphoma Cell by Upregulating Survivin.

Med Sci Monit 2019 Jan 12;25:365-370. Epub 2019 Jan 12.

Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China (mainland).

BACKGROUND LINK-A lncRNA acts as an oncogene in triple-negative breast cancer, but its involvement in other diseases is unknown. The present study was performed to investigate the involvement of LINK-A lncRNA in mantle cell lymphoma. MATERIAL AND METHODS Expressions of LINK-A lncRNA and survivin in plasma of patients with mantle cell lymphoma and healthy controls were detected by qRT-PCR and ELISA, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/MSM.912141DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339453PMC
January 2019
1 Read

Blastoid Variant Mantle Cell Lymphoma Expressing Aberrant CD3 and CD10 with Concurrent Small Lymphocytic Lymphoma: Establishment of a Clonal Relationship by B- and T-Cell Receptor Gene Rearrangements.

Case Rep Hematol 2018 5;2018:8303571. Epub 2018 Dec 5.

Medical Oncology and Hematology, 7777 Milliken Avenue Suite 210, Rancho Cucamonga, CA 91730, USA.

Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin B-cell lymphoma typically expressing CD19, CD20, CD5, FMC-7, CyclinD1, and SOX-11 and harboring the IgH/CCND1 translocation. We report a blastoid variant of mantle cell lymphoma (MCL) involving an inguinal lymph node that, in addition to classical phenotypic and genetic findings, also aberrantly coexpresses surface CD10 and cytoplasmic CD3. Small lymphocytic lymphoma (SLL) was also present in the same lymph node and in the bone marrow. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8303571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305046PMC
December 2018
4 Reads

Mantle Cell Lymphoma Case Report.

Case Rep Oncol 2018 Sep-Dec;11(3):814-821. Epub 2018 Dec 4.

Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation.

Introduction: Due to the beginning of the use of immunophenotypic and cytogenetic techniques, new nosological forms of lymphoproliferative diseases have appeared over the past few decades. According to the WHO classification (2008), today there are more than 50 known lymphoproliferative diseases.

Case Presentation: We present the case of a 51-year-old man with lymphoproliferative syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000492665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323362PMC
December 2018
2 Reads

Gastrointestinal Perforation after Rituximab Therapy in Mantle Cell Lymphoma: A Case Report.

Case Rep Oncol 2018 Sep-Dec;11(3):784-790. Epub 2018 Nov 29.

Department of Hematology/Oncology, Sinai Hospital, Baltimore, Maryland, USA.

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin lymphoma (NHL), responsible for 2.8% of all NHL cases within the United States. The majority of patients with MCL present with advanced disease, 10-20% of which have extra-nodal involvement at diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323410PMC
November 2018
2 Reads

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.

Leuk Lymphoma 2019 Jan 10:1-9. Epub 2019 Jan 10.

a Department of Internal Medicine - Hematology and Oncology , University Hospital Brno and Faculty of Medicine, Masaryk University , Brno, Czech Republic.

Mantle cell lymphoma (MCL) is characterized by the hallmark t(11;14)(q13;q32) translocation, leading to cyclin D1 over-expression. Additionally, disrupting the DNA damage response pathway through ATM or TP53 defects plays an important role in MCL pathogenesis. Using deep next-generation sequencing we analyzed the mutual composition of ATM and TP53 mutations in 72 MCL patients, and assessed their impact on progression-free survival (PFS) and overall survival (OS). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1542144DOI Listing
January 2019
8 Reads

Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature.

World J Clin Oncol 2018 Dec;9(8):200-207

Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.

Background: Epithelial-myoepithelial carcinoma (EMC) is a rare, low-grade, malignant tumor that constitutes less than one percent of all salivary gland tumors. To date, only one other case report has described radiation-associated EMC in the English language medical literature.

Case Summary: In this report, we describe the case of a 56-year-old male patient who presented with a neck mass diagnosed as EMC of the left submandibular gland approximately 30 years after mantle field radiation and chemotherapy for Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
https://www.wjgnet.com/2218-4333/full/v9/i8/200.htm
Publisher Site
http://dx.doi.org/10.5306/wjco.v9.i8.200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314863PMC
December 2018
2 Reads

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Ann Hematol 2019 Jan 8. Epub 2019 Jan 8.

Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.

Stage I non-Hodgkin lymphoma (NHL) is rare; prognostic impact of different histologic subtypes and treatment modality is still unclear. We used the Surveillance, Epidemiology and End Results (SEER) database to evaluate survival outcomes among adult patients (age ≥ 18 years, N = 58,230) diagnosed with stage I NHL of various histologic subtypes between 1998 and 2014. Five-year disease-specific survival of patients with stage I diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and peripheral T cell lymphoma (PTCL) was 82%, 92%, 95%, 89%, 78%, 77%, and 77%, respectively. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00277-018-3571-7
Publisher Site
http://dx.doi.org/10.1007/s00277-018-3571-7DOI Listing
January 2019
8 Reads

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

J Clin Oncol 2019 Feb 7;37(6):471-480. Epub 2019 Jan 7.

1 Fox Chase Cancer Center, Philadelphia, PA.

Purpose: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00690DOI Listing
February 2019
9 Reads
18.428 Impact Factor

Rapidly progressive neurologic decline and morbilliform rash presenting in a patient with lymphoma.

Clin Pract 2018 Oct 4;8(4):1097. Epub 2018 Dec 4.

Ronald Reagan UCLA Medical Center, University of California, Los Angeles, CA, USA.

A 67-year-old male with past medical history of mantle cell lymphoma and atrial fibrillation presented with a truncal rash, bilateral lower extremity weakness, and confusion. Within three days of presentation, his condition rapidly deteriorated with the onset of diffuse flaccid paralysis, aphasia, and severe alteration in mental status. Initial results from serum studies, lumbar puncture, magnetic resonance imaging, and electroencephalogram were not diagnostic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/cp.2018.1097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291742PMC
October 2018
1 Read

Lenalidomide for the treatment of mantle cell lymphoma.

Expert Opin Pharmacother 2019 Jan 4:1-8. Epub 2019 Jan 4.

b Biotechnology Research Unit, AO , Cosenza , Italy.

Introduction: Although a variety of therapeutic schemes for Mantle Cell Lymphoma (MCL) have been attempted, the clinical outcome of patients continues to be unsatisfactory especially among patients with a very high-risk profile and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel approaches, either by the use of biological agents in chemotherapy-free schedules or by integrating them with chemoimmunotherapy regimens. Areas covered: The efficacy of lenalidomide monotherapy and combination therapy established in clinical studies mainly involving relapsed/refractory MCL is reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561865DOI Listing
January 2019
3 Reads
3.534 Impact Factor

Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.

Medicine (Baltimore) 2019 Jan;98(1):e13741

The Bone Marrow Transplantation Center & Multiple Myeloma Treatment Center, The First Affiliated Hospital of Medical College, Zhejiang University.

Mantle cell lymphoma (MCL) is an invasive B-cell lymphoma with significant individual differences. Currently, MCL international prognostic index (MIPI) score and tumor cell proliferation index Ki-67 have been proved to be the most important prognostic factors. But the prognostic effect of these factors in Asian population is uncertain. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005792-201901040-0000
Publisher Site
http://dx.doi.org/10.1097/MD.0000000000013741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344161PMC
January 2019
3 Reads

Osteoclast-like giant cell tumor of the pancreas-an unusual presentation in a patient with large mantle cell lymphoma.

J Surg Case Rep 2018 Dec 21;2018(12):rjy341. Epub 2018 Dec 21.

Department of Surgery, SUNY Upstate Medical University, Syracuse, NY 13210, USA.

Osteoclast-like giant cell tumor of the pancreas is very rare. We report a 78-year-old male who was previously treated for large mantle cell lymphoma, was found to have an increased uptake in a peri-pancreatic node from his restaging PET scan. Endoscopic ultrasound-directed fine-needle aspiration of the mass and lymph node revealed an undifferentiated carcinoma with osteoclast-like giant cells. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jscr/article/doi/10.1093/jscr/rjy34
Publisher Site
http://dx.doi.org/10.1093/jscr/rjy341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302238PMC
December 2018
1 Read

Noninfectious Cloudy Peritoneal Effluent in a Peritoneal Dialysis Patient with Mantle Cell Lymphoma.

Cureus 2018 Oct 4;10(10):e3413. Epub 2018 Oct 4.

Internal Medicine, University of New Mexico School of Medicine, Albuquerque, USA.

A 77-year-old man on peritoneal dialysis (PD) presented repeatedly with cloudy spent dialysate containing an elevated mononuclear cell count. He had mantle cell lymphoma diagnosed by colonic polyp biopsy two years before the start of PD. The first episode of cloudy dialysate was treated for peritonitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300385PMC
October 2018
1 Read